- PluriSIn #1 (NSC 14613)
- Gimeracil
- Mycophenolate Mofetil
- Trilostane
- AGI-5198
- CPI-613
| Alda 1ALDH2 activator |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.96%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Kinase experiment [1]: | |
Kinase assays | Dehydrogenase activity was measured as conversion of NAD (1 mM) to NADH in the presence of formaldehyde, acetaldehyde, or propionaldehyde (1 mM each) by monitoring the change in absorbance at 340 nm at 25 °C. The reactions were performed in 50 mM sodium pyrophosphate buffer (pH 9.0) containing 10 mM MgCl2 and 10 μM Alda-1 or 0.5% (v/v) DMSO as a vehicle control. |
| Animal experiment [2]: | |
Animal models | Mouse xenograft SCC VII tumor model |
Dosage form | Alda-1 (3 mM in 95% ethanol solution in a volume of 0.25 ml) was applied locally on the skin. |
Application | Concomitant topical application of the ALDH2 activator, Alda-1, effectively reduced the severity and delayed the onset of radiation-induced dermatitis in mice. Therefore, Alda-1, may be used as an adjunct to radiation therapy for the treatment of solid tumors in which radiation-induced dermatitis is an important clinical problem. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Beretta M, Gorren AC, Wenzl MV, Weis R, Russwurm M, Koesling D, Schmidt K, Mayer B. Characterization of the East Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1. J Biol Chem. 2010 Jan 8;285(2):943-52. [2] Ning S, Budas GR, Churchill EN, Chen CH, Knox SJ, Mochly-Rosen D. Mitigation of radiation-induced dermatitis by activation of aldehyde dehydrogenase 2 using topical alda-1 in mice. Radiat Res. 2012 Jul;178(1):69-74. | |
Alda 1 Dilution Calculator
calculate
Alda 1 Molarity Calculator
calculate
| Cas No. | 349438-38-6 | SDF | Download SDF |
| Chemical Name | N-(benzo[d][1,3]dioxol-5-ylmethyl)-2,6-dichlorobenzamide | ||
| Canonical SMILES | ClC1=CC=CC(Cl)=C1C(NCC2=CC=C3OCOC3=C2)=O | ||
| Formula | C15H11Cl2NO3 | M.Wt | 324.16 |
| Solubility | ≥15.15mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
IC50: N/A
Alda 1 is an activator of aldehyde dehydrogenase 2 (ALDH2).
Alda 1 increases activity of wild-type ALDH2*1 and variant ALDH2*2 (by ~2-fold and 11-fold respectively), Capable of partly restoring mutant ALDH2*2 activity, and protective against cardiac ischemia.
In vitro: In the present study , Alda-1 increased acetaldehyde oxidation by ALDH2*1 and ALDH2*2 approximately 1.5- and 6-fold, respectively, regarding GTN bioactivation and the effects of Alda-1. To similar extent, Alda-1 induced the esterase activities of both enzymes as the coenzyme NAD. NAD pronounced inhibition occurring at > 5mM, its the effect was biphasic. In the presence of 1 mM NAD, Alda-1 induced ALDH2*2-catalyzed ester hydrolysis 73-fold, whereas the NAD-induced activity of ALDH2*1 was inhibited on account of 20-fold increased inhibitory potency of NAD in the presence of the drug. ALDH2*2 displayed 7-fold lower GTN denitrating activity and GTN affinity than ALDH2*1, but the rate of nitric oxide formation was only reduced 2-fold. Soluble guanylate cyclase (sGC) activation was more pronounced than with wild type ALDH2 at saturating GTN. Alda-1 caused slight inhibition of GTN denitration, and in the presence of either variant, GTN-induced sGC activation was increased. The present results imply that established ALDH2 activities stimulated by Alda-1, which improved NAD binding but does not improve the GTN binding affinity of the Asian variant. In addition, an unexpected discrepancy between GTN reductase activity and sGC activation was revealed, which suggested that GTN denitration and bioactivation may display independent pathways of ALDH2-catalyzed GTN biotransformation [1].
In vivo: Alda-1 (a high-throughput screen yielded a small-molecule activator of ALDH2, administered to rats before an ischemic event) reduced infarct size by 60%, most likely through the inhibition ofthe formation of cytotoxic aldehydes. Thus, pharmacologic enhancement of ALDH2 activity may be benefit to patients with wild-type or mutant ALDH2 who are subjected to cardiac ischemia, such as during coronary bypass surgery [2].
Clinical trial: Clinical study has been conducted.
References:[1]. Beretta M, Gorren AC, Wenzl MV, Weis R, Russwurm M, Koesling D, Schmidt K, Mayer B. Characterization of the East Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1. J Biol Chem. 2010 Jan 8;285(2):943-52. [2]. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 2008 Sep 12;321(5895):1493-5.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
总局关于发布医用磁共振成像系统临床评价等4项医疗器械注册技术审查指导原则的通告（2017年第6号）
2017年01月16日发布http://www.sfda.gov.cn/WS01/CL0087/168596.html
为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家食品药品监督管理总局组织制定了《医用磁共振成像系统临床评价技术审查指导原则》《口腔颌面锥形束计算机体层摄影设备注册技术审查指导原则》《体外除颤产品注册技术审查指导原则》《光固化机注册技术审查指导原则》（见附件），现予发布。
特此通告。
附件：1.医用磁共振成像系统临床评价技术审查指导原则
2.口腔颌面锥形束计算机体层摄影设备注册技术审查指导原则
3.体外除颤产品注册技术审查指导原则
4.光固化机注册技术审查指导原则
食品药品监管总局
2017年1月10日
2017年第6号通告附件1.docx
2017年第6号通告附件2.docx
2017年第6号通告附件3.doc
2017年第6号通告附件4.docx
图1 光声成像工程 (a)光声信号激发与探测；(b)光声成像实现过程示意图
光声成像过程可以分为三个部分：信号的产生、信号的接收和信号处理及图像重建（见图1）。由于脉冲激光器具有光声转换效率高的优点，因此通常被作为光声成像研究中产生信号的激励源。脉冲激光器发出的激光束照射在待研究组织样品上，由于组织样品的吸收效应，在样品内部形成了与组织光学参数相关的能量沉积分布。由于激光脉宽很窄（ns）吸收的能量不能在短时间内释放，导致瞬间温度变化，从而通过热弹机制转化为热膨胀。周期性热流使周围的介质热胀冷缩而激发超声波，由于这种超声波信号的特殊产生机理，为了区别于其它的超声信号，通常称为光声信号。利用超声探测器接收光声信号并对采集到的信号进行适当地处理和采用相应的图像重建算法，就能够得到样品内部光能量沉积的分布。当保证入射光的均匀性的前提下，光声重建图像与吸收分布具有一一对应的关系。向左转|向右转
光系统设计难各种光系统都各自特点所像质优化重点全致 没像数或者物理领域种著名课题 希望能帮
请问成像系统工作站请问那家的产品做得比较好以及专业一些呢？
实验室新组建，想咨询一下Camag薄层色谱成像系统的价格及一套显微成像的设备清单与价格。显微成像主要用于中药材的显微鉴别
显微镜是OlympusDP71，弄比例尺的时候出来个“衸”，这是什么鬼啊？如何换算成微米？测量的那个选项我选的是10微米，也只有那个选项可以点。然后倍数选择200，然后他就出来这个200衸，选100倍数是500衸，400倍是200也衸，但长度是200的两倍，**各位大神帮帮忙，要怎样才能换成微米？另外1衸是多少微米？
